CD44 and triple-negative breast carcinoma: Based on this, Zheng et al. reported multivalent antibody recruitment molecules (ARMs) with dual targeting tumor terminal (TBT), including hyaluronic acid (natural ligand targeting CD44) targeting clustered 44 (CD44, a transmembrane glycoprotein, overexpressed in breast cancer and triple negative breast cancer) and nano antibody 7D12 or peptide GE11.7D12 targeting epidermal growth factor receptor (EGFR, overexpressed in tumor cells).